Optimizing Finerenone Therapy: A Comprehensive Review Using the “Finerenone Pentad”
DOI:
https://doi.org/10.59793/ijcp.v34i7.742Keywords:
Chronic kidney disease, type 2 diabetes,, selective nonsteroidal mineralocorticoid receptor antagonistAbstract
Chronic kidney disease (CKD) is a pressing global health concern, often intertwined with comorbid conditions such as type 2
diabetes mellitus (T2DM) and cardiovascular complications. Managing CKD in T2DM patients requires a multifaceted approach,
and emerging therapeutic options are increasingly essential. Finerenone, a selective nonsteroidal mineralocorticoid receptor
antagonist, has shown considerable promise in addressing the intricate cardiorenal needs of these patients. To maximize the
effectiveness of this therapy, we propose the approach of “Finerenone Pentad” which can be utilized as a checklist while starting
and subsequently monitoring the finerenone therapy. This structured approach offers guidance on patient selection, monitoring
and outcome evaluation, ensuring a holistic approach to the care of individuals with T2DM and CKD.
Downloads
Published
Issue
Section
License
All open access articles published in IJCP are distributed under the terms of the CC BY-NC 4.0 license (Creative Commons Attribution-Non-Commercial 4.0 International Public License). This license permits unrestricted use, distribution, and reproduction of the articles in any medium for non-commercial purposes, provided that: The original authorship is properly and fully attributed. The IJCP is cited as the original place of publication with correct citation details. If an original work is reproduced or disseminated in part or as a derivative work, this must be clearly indicated. No articles are reproduced for commercial use without prior consent from the IJCP. All licensing requests and permissions for commercial use will be managed by the Publisher.
How to Cite
